CVS Health Corporation

NYSE:CVS Stock Report

Market Cap: US$105.4b

CVS Health Valuation

Is CVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CVS ($83.01) is trading below our estimate of future cash flow value ($178.64)

Significantly Below Future Cash Flow Value: CVS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CVS?

Key metric: As CVS is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CVS. This is calculated by dividing CVS's market cap by their current revenue.
What is CVS's PS Ratio?
PS Ratio0.3x
SalesUS$391.69b
Market CapUS$105.38b

Price to Sales Ratio vs Peers

How does CVS's PS Ratio compare to its peers?

The above table shows the PS ratio for CVS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5x
CI Cigna Group
0.3x3.96%US$74.6b
LH Labcorp Holdings
1.6x4.47%US$22.1b
DGX Quest Diagnostics
1.9x3.76%US$20.1b
GH Guardant Health
16.4x20.90%US$14.8b
CVS CVS Health
0.3x4.26%US$105.4b

Price-To-Sales vs Peers: CVS is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does CVS's PS Ratio compare vs other companies in the US Healthcare Industry?

30 CompaniesPrice / SalesEstimated GrowthMarket Cap
COR Cencora
0.2x6.15%US$68.76b
CAH Cardinal Health
0.2x8.18%US$49.50b
CNC Centene
0.1x2.67%US$22.65b
MOH Molina Healthcare
0.2x5.36%US$10.38b
CVS 0.3xIndustry Avg. 1.3xNo. of Companies30PS012345+
30 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CVS is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Healthcare industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is CVS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CVS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: CVS is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CVS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$83.01
US$94.96
+14.40%
6.20%US$105.00US$79.00n/a25
Jan ’27US$79.36
US$94.60
+19.20%
6.29%US$105.00US$79.00n/a25
Dec ’26US$79.10
US$91.48
+15.65%
7.21%US$102.00US$77.00n/a25
Nov ’26US$78.15
US$91.08
+16.55%
7.66%US$103.00US$77.00n/a25
Oct ’26US$76.87
US$82.50
+7.32%
7.64%US$99.00US$70.00n/a24
Sep ’26US$73.15
US$81.57
+11.51%
8.16%US$99.00US$70.00n/a24
Aug ’26US$62.47
US$79.91
+27.91%
8.61%US$95.00US$67.00n/a24
Jul ’26US$69.58
US$79.73
+14.59%
7.11%US$95.00US$71.00n/a25
Jun ’26US$64.04
US$79.61
+24.31%
7.28%US$95.00US$71.00n/a25
May ’26US$69.45
US$76.65
+10.36%
7.54%US$90.00US$67.00n/a25
Apr ’26US$67.98
US$72.26
+6.29%
11.06%US$86.00US$48.01n/a25
Mar ’26US$65.72
US$72.14
+9.77%
13.08%US$91.43US$48.01n/a25
Feb ’26US$56.48
US$65.58
+16.11%
16.51%US$93.00US$48.01n/a25
Jan ’26US$44.89
US$66.26
+47.60%
16.19%US$93.00US$48.01US$79.3625
Dec ’25US$59.85
US$68.35
+14.20%
13.55%US$93.00US$57.00US$79.1025
Nov ’25US$55.81
US$69.46
+24.45%
14.45%US$93.00US$59.00US$78.1525
Oct ’25US$61.54
US$67.14
+9.09%
14.02%US$93.00US$59.00US$76.8725
Sep ’25US$57.24
US$67.26
+17.50%
13.04%US$93.00US$59.00US$73.1525
Aug ’25US$60.03
US$67.74
+12.84%
13.10%US$93.00US$58.00US$62.4725
Jul ’25US$58.15
US$69.10
+18.82%
13.42%US$93.00US$59.00US$69.5826
Jun ’25US$59.60
US$69.02
+15.80%
13.50%US$93.00US$59.00US$64.0426
May ’25US$56.31
US$84.69
+50.40%
10.81%US$101.00US$60.00US$69.4526
Apr ’25US$79.56
US$89.46
+12.44%
7.50%US$103.00US$77.00US$67.9826
Mar ’25US$73.84
US$89.74
+21.54%
6.96%US$103.00US$77.00US$65.7225
Feb ’25US$73.92
US$90.66
+22.65%
7.39%US$104.00US$80.00US$56.4824
Jan ’25US$78.96
US$88.41
+11.97%
8.58%US$104.00US$76.00US$44.8924
US$94.96
Fair Value
12.6% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/25 17:28
End of Day Share Price 2026/01/23 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CVS Health Corporation is covered by 49 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harshit GuptaAccountability Research Corporation
Christopher GrajaArgus Research Company
Hua HaBaird